Pfizer COVID-19 vaccine protects kids against infection, is less effective against omicron

The Pfizer-BioNTech COVID-19 vaccine reduced the risk for infection with the omicron variant of SARS-CoV-2 by 31% among children aged 5 to 11 years and 59% among adolescents aged 12 to 15 years, according to data published Friday in MMWR.
The real-world study also found that the vaccine was 87% effective against infection with the delta variant among adolescents. The variant surged before younger children had access to the vaccine.
“Real-world data on vaccine effectiveness (VE) in these age groups are needed, especially because when the omicron variant became predominant in the United

The Pfizer-BioNTech COVID-19 vaccine reduced the risk for infection with the omicron variant of SARS-CoV-2 by 31% among children aged 5 to 11 years and 59% among adolescents aged 12 to 15 years, according to data published Friday in MMWR.
The real-world study also found that the vaccine was 87% effective against infection with the delta variant among adolescents. The variant surged before younger children had access to the vaccine.
“Real-world data on vaccine effectiveness (VE) in these age groups are needed, especially because when the omicron variant became predominant in the United